RxDoctor Payments Data

Sanjay Raisoni, MD

Internal Medicine · San Francisco, CANPI 1891937785

Payments from drug & device makers

$897in general payments, 2019–2025

Across 21 payments — averaging $42.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$300
  • Bayer$157
  • Abbott$93
  • Vertos Medical, Inc.$75
  • Merz North America, Inc.$70
  • AbbVie$55
  • plus $148 from 6 others

What the payments were for

  • Food & beverage$897100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$897 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$68,170
Medicare patients
138
Services billed
3,396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$41,721
EliquisApixaban28$34,204
Celecoxib58$3,104
Atorvastatin Calcium147$2,319
Tamsulosin Hcl29$1,162
Levothyroxine Sodium80$1,105
Escitalopram Oxalate52$1,101
Olmesartan Medoxomil24$1,040
Omeprazole38$682
Losartan Potassium45$639
Potassium Chloride30$632
Lisinopril47$586
Metoprolol Tartrate54$584
Nifedipine ErNifedipine22$584
Metoprolol Succinate30$559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$300$41,72136 claims
PfizerEliquis$16$34,20428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →